Published in Blood Weekly, June 14th, 2001
MELD has been shown to predict mortality in patients undergoing transjugular intrahepatic portosystemic shunt surgery and in those with cirrhosis who do not require a liver transplant.
To see if the model predicts mortality in patients awaiting liver transplants, researchers at the University of Nebraska Medical Center, Omaha, followed 70 patients and used MELD to calculate risk scores.
MELD successfully separated patients into low- and high-risk groups; over 12 months,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2001-06-14)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.